Medistim ASA (OSL:MEDI) Total Liabilities: kr175.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:MEDI Medistim ASA OSL:MEDI
88 GF Score
Price kr230.00
GF Value kr259.67
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medistim ASA Total Liabilities?

Medistim ASA OSL:MEDI -1.71% 88 Total Liabilities is kr175.1 Mil as of Mar. 2026. GuruFocus rates OSL:MEDI with a GF Score™ of 88/100 and a GF Value™ of kr259.67 (Modestly Undervalued). The stock has 1 warning sign investors should review.

Medistim ASA's Total Liabilities for the quarter that ended in Mar. 2026 was kr175.1 Mil.

Medistim ASA's quarterly Total Liabilities increased from Sep. 2025 (kr156.57 Mil) to Dec. 2025 (kr192.20 Mil) but then declined from Dec. 2025 (kr192.20 Mil) to Mar. 2026 (kr175.14 Mil).

Medistim ASA's annual Total Liabilities increased from Dec. 2023 (kr107.78 Mil) to Dec. 2024 (kr138.36 Mil) and increased from Dec. 2024 (kr138.36 Mil) to Dec. 2025 (kr192.20 Mil).

Medistim ASA Total Liabilities Historical Data

* Premium members only.

The historical data trend for Medistim ASA's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medistim ASA Total Liabilities Chart

Medistim ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 97.19 114.97 107.78 138.36 192.20

Medistim ASA Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 150.90 151.23 156.57 192.20 175.14
OSL:MEDI
88GF Score
Medistim ASA OSL:MEDI
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medistim ASA Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Medistim ASA's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=143.209+(37.677+11.309
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=192.2

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=660.601-468.406
=192.2

Medistim ASA's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=129.641+(34.595+10.905
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=175.1

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=681.885-506.744
=175.1

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of kr175.1 Mil mean?
Medistim ASA (OSL:MEDI) has a Total Liabilities of kr175.1 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Medistim ASA and its competitors.
Is Medistim ASA's Total Liabilities too high?
Medistim ASA's current Total Liabilities is kr175.1 Mil. Overall, Medistim ASA has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medistim ASA's Total Liabilities compare to ABT and SYK?
Medistim ASA's Total Liabilities of kr175.1 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Medistim ASA and its competitors. Medistim ASA's current Total Liabilities is kr175.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medistim ASA stock overvalued right now?
Based on GuruFocus' analysis, Medistim ASA (OSL:MEDI) is currently considered Modestly Undervalued. The stock's GF Value™ is kr259.67, compared to a current price of kr230.00 — trading 11.4% below its estimated fair value. The current Total Liabilities is kr175.1 Mil. Medistim ASA's overall GF Score™ is 88/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Medistim ASA (OSL:MEDI), the current Total Liabilities is kr175.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medistim ASA (OSL:MEDI) Overvalued in 2026?

Based on GuruFocus' analysis, Medistim ASA stock appears to be undervalued. The current stock price of kr230.00 is trading 11.4% below its estimated GF Value™ of kr259.67. GuruFocus considers Medistim ASA to be Modestly Undervalued.

Key valuation signals for OSL:MEDI:

  • Total Liabilities: kr175.1 Mil
  • GF Value™: kr259.67 vs. price of kr230.00 (11.4% below fair value)
  • GF Score™: 88/100 with 1 warning sign

No single metric tells the full story. See the OSL:MEDI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medistim ASA Business Description

Address Okernveien 94, Oslo, NOR, 0579
Medistim ASA is a medical device company. It is engaged in researching, developing, producing, distributing, and sales of medical equipment through its own business or participation in other companies, as well as related activities. The company's business is focused on cardiac and vascular surgery. The group operates in the USA, Europe, China, and the Rest of the World. The main divisions are sale of own products and sale of third-party products. Sale of own products has two business models, the capital model and the lease model. Third-party products segment sells medical devices from third party manufacturers in Norway, Sweden and Denmark. Key revenue is generated from Own Products segment.
88GF Score

Get the complete analysis for OSL:MEDI

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr230.00
Price
kr259.67
GF Value